Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Entero Healthcare Solutions Ltd

₹ 1,112-0.98%
05 Jan – close price
🔗enterohealthcare.com•BSE: 544122•NSE: ENTERO
Market Cap₹ 4,841 Cr.
Current Price₹ 1,112
High / Low₹ 1,565
Stock P/E113
Book Value₹ 384
Dividend Yield0.00 %
ROCE4.54 %
ROE3.22 %
Face Value₹ 10.0
Sales₹ 336 Cr.
OPM-14.5 %
Mar Cap₹ 4,841 Cr.

ABOUT

Incorporated in 2018, Entero HealthcareSolutions Ltd is in the business of distributionand marketing of pharmaceutical and surgical products and allied services[1]

KEY POINTS

Business Overview:[1]EHSL, a leading Healthcare Supply Chain Solutions Specialist, ranks among India’s top three healthcare product distributors by revenue, offering demand fulfillment and generation solutions to manufacturers.

Also present in buckets:
Aggressive Growth TriggersExcellent ResultsRevenue GuidanceAsset Base ExpansionCapacity Expansion And ProductsPreferential IssuanceJv Partnerships AcquisitionsRevenue Guidance Vs ActualsCredit Rating UpdatesRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Medplus Health832.5051.139975.230.0055.5043.261679.336.5410.286293.028.72195.0955.505.414.590.65
2.Entero Healthcar1112.50113.344840.590.005.70-62.8283.22-26.244.54336.02-14.5042.715.702.902.950.02
–Median: 2 Co.972.582.237407.910.030.6-9.78881.27-9.857.413314.52-2.89118.930.64.163.770.34

Quarterly Results

Standalone figures in ₹ crores

Dec 2022Dec 2023Dec 2024Jun 2023Jun 2024Jun 2025Mar 2023Mar 2024Mar 2025Sep 2023Sep 2024Sep 2025
Sales
54.8276.59101.1561.20122.3879.3550.35106.5672.3073.81112.8383.22
Expenses
64.5085.09111.6368.82124.2393.0657.79115.7584.2383.00118.9095.81
Operating Profit
-9.68-8.50-10.48-7.62-1.85-13.71-7.44-9.19-11.93-9.19-6.07-12.59
Other Income
14.3116.2527.5114.7632.1726.2913.9342.40-21.2116.5228.8124.23
Profit before tax
-0.980.7014.470.0827.749.170.6425.87-35.65-2.2820.227.61
Tax %
0.00%-35.71%25.50%-2,837.50%24.77%24.10%0.00%-44.11%-22.02%-6.14%24.18%25.10%
Net Profit
-0.980.9510.782.3620.886.960.6437.28-27.81-2.1415.335.70
EPS in Rs
-2.380.592.485.744.801.601.568.57-6.39-1.333.521.31

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
56105137178318409336
Expenses
73137191222353439385
Operating Profit
-17-32-54-44-34-30-49
Other Income
21232753906757
Interest
125112222
Depreciation
479109910
Profit before tax
-2-18-41-122427-4
Net Profit
-2-18-41-123819-4
EPS in Rs
-162.67-1,811.38-106.10-30.318.844.41-1.00
Dividend Payout %
0%0%0%0%0%0%–

Compounded Profit Growth

10 Years:%
5 Years:103%
3 Years:49%
TTM:-43%

Compounded Sales Growth

10 Years:%
5 Years:49%
3 Years:44%
TTM:-20%

Return on Equity

10 Years:%
5 Years:%
3 Years:%
Last Year:3%

Stock Price CAGR

10 Years:%
5 Years:%
3 Years:%
1 Year:-21%

Balance Sheet

Standalone figures in ₹ crores

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
0.100.1044434444
Reserves
-13-31-72-841,5831,6071,627
Borrowings
457540674775181428
Other Liabilities
21234768125139129
Total Liabilities
4665336547641,7691,8041,827
Fixed Assets
46505141342848
Gross Block
50.5762.2372.1769.6372.1173.40–
Accumulated Depreciation
4.7012.0420.7528.9837.6745.11–
CWIP
220-0-00-0
Investments
3839394141277327
Other Assets
3804425636821,6941,4981,451
Total Assets
4665336547641,7691,8041,827

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
-52-68-45-57-76-109
Cash from Investing Activity
-167-7-69-58-763208
Cash from Financing Activity
1787612791926-41
Net Cash Flow
-41014-248758

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
11410713915313089
Inventory Days
2061771036865110
Days Payable
10148991328887
Cash Conversion Cycle
21923614389107112
Working Capital Days
2,0131,2011,034947850432
ROCE %
–-3%-6%-0%4%5%

Shareholding Pattern

Numbers in percentages

Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
52.44%52.44%52.44%52.44%52.42%52.42%52.42%
FIIs
23.30%23.32%23.82%22.20%19.92%17.21%14.68%
DIIs
2.28%2.06%7.73%8.78%9.63%10.19%9.64%
Public
21.99%22.18%16.02%16.59%18.03%20.19%23.26%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Entero Healthcare Announces Trading Window Closure Ahead of Results

23rd March 2026, 10:48 pm

Entero Healthcare Announces Resignation of President - Institutional Business

12th March 2026, 1:39 am

Entero Healthcare to Meet Investors on March 11, 2026

5th March 2026, 1:33 am

Entero Healthcare Announces Analyst & Investor Meetings for March 6, 2026

27th February 2026, 12:57 am

Multiple Companies Unveil Q3 FY26 Financial Results and Corporate Updates

21st February 2026, 9:09 pm

Published by Other Websites

External media mentions & references

US Tariff Threat Hits Indian Pharma Stocks Hard, Index Down 3%

2nd April 2026, 11:10 am

Healthcare Gems: Triple-Digit Profit Growth Faces Valuation Discount

21st March 2026, 6:08 am

DIIs Bet Big on Microcaps Amidst Market Plunge: 5 Stocks Gain Institutional Focus

8th March 2026, 6:49 am

Jefferies Forecasts Weak Pharma H1 2026; Names Top Stock Picks

8th January 2026, 11:54 am

ICICI Prudential CIO S Naren's Secret Strategy: Find These Unloved Stocks for Big Gains!

1st January 2026, 2:16 pm

News Articles

Editorial & research coverage

Jefferies Forecasts Weak Pharma H1 2026; Names Top Stock Picks
Jefferies Forecasts Weak Pharma H1 2026; Names Top Stock Picks

8th January 2026, 11:54 am

ICICI Prudential CIO S Naren's Secret Strategy: Find These Unloved Stocks for Big Gains!
ICICI Prudential CIO S Naren's Secret Strategy: Find These Unloved Stocks for Big Gains!

1st January 2026, 2:16 pm

Entero Healthcare Acquires Anand Chemiceutics, Eyes INR 1,000 Cr MedTech Revenue
Entero Healthcare Acquires Anand Chemiceutics, Eyes INR 1,000 Cr MedTech Revenue
Entero Healthcare Q3: Revenue Up 25%, EBITDA Soars 35% on Acquisitions
Entero Healthcare Q3: Revenue Up 25%, EBITDA Soars 35% on Acquisitions

Documents

Announcements

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Closure of Trading Window
Intimation For Grant Of 73060Options Pursuant To "Entero Employees Stock Options Plan 2023" To The Eligible Employees Of The Company

6 Dec - Granted 73,060 ESOPs under Entero ESOP 2023 at INR 804 each, vesting 1–4 years, grant date Dec 06, 2025.

Announcement under Regulation 30 (LODR)-Credit Rating

4 Dec 2025 - India Ratings affirmed Entero Healthcare issuer rating IND A-/Stable on December 03, 2025.

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Credit Ratings

Rating update

3 Dec 2025 from fitch

Rating update

9 Sep 2024 from fitch

Rating update

11 Feb 2021 from fitch

Concalls

Nov 2025

TranscriptPPTRecording

Aug 2025

TranscriptPPT

Jun 2025

TranscriptPPT

Feb 2025

Transcript

Feb 2025

TranscriptPPT

Nov 2024

TranscriptPPT

Aug 2024

TranscriptPPT

Jun 2024

TranscriptPPTRecording

May 2024

PPT

Mar 2024

TranscriptPPT

Stock Analysis

Description

  1. Entero Healthcare Solutions Ltd is a leading healthcare supply chain solutions specialist and one of India's top three healthcare product distributors. It offers demand fulfillment and generation solutions to manufacturers across pharmaceuticals and surgical products.

Key Growth Triggers

  1. The company focuses on organic expansion and disciplined M&A, particularly in the MedTech segment, to enhance its distribution network and market presence. Recent acquisitions aim to bolster its capabilities, supported by management's reiterated full-year guidance for profitable growth.

Order Book

  1. Currently no data available for Order Book.

Key Red Flags

  1. Standalone revenue has experienced declines in certain periods. Historically, the company faced challenges with debtor days and cash conversion cycles, though improvements have been noted.

Key Dates To Watch

  1. Upcoming investor and analyst meetings, board meetings for financial results, and ongoing acquisition completion timelines.

Corporate Announcements

23rd Mar 26
Impact Rating: 6
Entero Healthcare Solutions announced the closure of its trading window from April 1, 2026. This will continue until 48 hours after its audited financial results for the period ending March 31, 2026, are declared.
11th Mar 26
Impact Rating: 6
Entero Healthcare Solutions Limited informed exchanges that Mr. Sambit Mohanty, President – Institutional Business, has resigned. He will cease to be a Senior Management Personnel from March 31, 2026, to pursue other career opportunities.
4th Mar 26
Impact Rating: 5
Entero Healthcare Solutions Limited has scheduled a group meeting with investors and analysts on March 11, 2026, in Mumbai, as part of the Investec India Promoter & Founder Conference 2026. Discussions will be limited to publicly available information.
26th Feb 26
Impact Rating: 5
Officials from Entero Healthcare Solutions Limited will meet with investors and analysts on March 6, 2026, in a virtual group meeting organized by Nirmal Bang Institutional Equities.
21st Feb 26
Impact Rating: -
No description available.